Haemonetics (NYSE: HAE) reported Q3 EPS of $0.48, $0.02 better than the analyst estimate of $0.46. Revenue for the quarter came in at $233.4 million versus the consensus estimate of $237.37 million.

Haemonetics reaffirmed FY2016 guidance.

For earnings history and earnings-related data on Haemonetics (HAE) click here.